Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: A double-blind, placebo-controlled cross-over trial

Journal of Hypertension

Volumn 31, Issue 2, 2013, Pages 393-403

  Dorresteijn, Johannes A N ^a   Schrover, Ilse M ^a   Visseren, Frank L J ^a   Scheffer, Peter G ^b   Liam Oey, P ^a   Jan Danser, A H ^c   Spiering, Wilko ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

endothelial function; hypertension; obesity; renin angiotensin system; sympathetic nervous system

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ADIPONECTIN; ALISKIREN; C REACTIVE PROTEIN; HYDROCHLOROTHIAZIDE; INSULIN; LEPTIN; MALONALDEHYDE; MOXONIDINE; MYELOPEROXIDASE; PLACEBO; POTASSIUM;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENDOTHELIAL FUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FEMALE; FOLLOW UP; HEART RATE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN SENSITIVITY; KIDNEY FUNCTION; MALE; MYALGIA; OBESITY; OXIDATIVE STRESS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; VASODILATATION; XEROSTOMIA;

EID: 84872870881     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835b6c02     Document Type: Article

References (32)

1. Dorresteijn JA, Visseren FL, Spiering W. Mechanisms linking obesity to hypertension. Obes Rev 2012; 13:17-26.
2. Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 2012; 30:1047-1055.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
4. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
5. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152:726-732.
6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
7. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45:142-161.
8. Rudenski AS, Matthews DR, Levy JC, Turner RC. Understanding 'insulin resistance': both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 1991; 40:908-917.
9. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a metaanalysis. Int J Cardiovasc Imaging 2010; 26:631-640.
10. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31:1865-1871.
11. Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol 2005; 45:1980-1986.
12. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009; 27:1493-1501.
13. Virdis A, Ghiadoni L, Qasem AA, Lorenzini G, Duranti E, Cartoni G, et al. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. Eur Heart J 2012; 33:1530-1538.
14. Perl S, Schmolzer I, Sourij H, Pressl H, Eder M, Zweiker R, Wascher TC. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance. Int J Cardiol 2008; 139:289-296.
15. Souza-Barbosa LA, Ferreira-Melo SE, Ubaid-Girioli S, Arantes Nogueira E, Yugar-Toledo JC, Moreno H Jr. Endothelial vascular function in hypertensive patients after renin-angiotensin system blockade. J Clin Hypertens (Greenwich) 2006; 8:803-809.
16. Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16:123-128.
17. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119:530-537.
18. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49:1047-1055.
19. Boschmann M, Nussberger J, Engeli S, Danser AH, Yeh CM, Prescott MF, et al. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. J Hypertens 2012; 30:561-566.
20. Krone W, Hanefeld M, Meyer HF, Jung T, Bartlett M, Yeh CM, et al. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens 2011; 25:186-195.
21. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15:3126-3133.
22. Seed A, Gardner R, McMurray J, Hillier C, Murdoch D, MacFadyen R, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007; 9:1120-1127.
23. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, et al. Adipocytes produce aldosterone through calcineurindependent signaling pathways: implications in diabetes mellitusassociated obesity and vascular dysfunction. Hypertension 2012; 59:1069-1078.
24. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012; 33:1058-1066.
25. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract 2006; 60:621-629.
26. Topal E, Cikim AS, Cikim K, Temel I, Ozdemir R. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006; 6:343-348.
27. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21:1761-1769.
28. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant 2011; 26:2930-2934.
29. Skalska A, Gasowski J, Stepniewski M, Grodzicki T. Antioxidative protection in hypertensive patients treated with diuretics. Am J Hypertens 2005; 18:1130-1132.
30. Whaley-Connell A, Purkayastha D, Yadao A, Sowers JR. Central pressure and biomarker responses to renin inhibition with hydrochlorothiazide and ramipril in obese hypertensives: the ATTAIN study. Cardiorenal Med 2011; 1:53-66.
31. Fogari R, Zoppi A, Mugellini A, Lazzari P, Derosa G. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Horm Metab Res 2010; 42:892-896.
32. Lumb PJ, McMahon Z, Chik G, Wierzbicki AS. Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract 2004; 58:465-468.